360 High-Risk Vulnerability Immunization Tool V2.0 vs Rapid7 Nexpose: Side-by-Side Comparison (2026)

360 High-Risk Vulnerability Immunization Tool V2.0

Startups and SMBs with Windows-heavy infrastructure and patching backlogs should run 360 High-Risk Vulnerability Immunization Tool V2.0 first; it immunizes against the specific CVEs that drive ransomware campaigns (MS17-010, CVE-2019-0708) without requiring immediate OS updates. The tool supports Windows 7 through current versions and deploys on-premises, meaning air-gapped networks can actually use it. Skip this if you're looking for NIST PR.PS coverage beyond platform hardening,this tool stops known exploits, not supply chain attacks or firmware-level threats.

Rapid7 Nexpose

Mid-market and enterprise security teams managing on-premises infrastructure will get the most from Rapid7 Nexpose because its Real Risk Score actually deprioritizes noise by factoring in exploit availability and vulnerability age, not just CVSS severity. The tool covers NIST ID.AM and ID.RA effectively through asset discovery, dynamic tagging, and VMware/AWS integration that keeps pace with environment changes. Skip this if you need cloud-native vulnerability scanning across containerized workloads; Nexpose is built for traditional datacenter and hybrid environments where you own the infrastructure.